(NASDAQ: PACB) Pacific Biosciences Of California's forecast annual revenue growth rate of 13.16% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.25%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.36%.
Pacific Biosciences Of California's revenue in 2025 is $152,357,000.On average, 5 Wall Street analysts forecast PACB's revenue for 2025 to be $46,547,935,998, with the lowest PACB revenue forecast at $45,459,828,931, and the highest PACB revenue forecast at $47,713,464,915. On average, 5 Wall Street analysts forecast PACB's revenue for 2026 to be $56,935,967,539, with the lowest PACB revenue forecast at $53,745,167,084, and the highest PACB revenue forecast at $59,524,498,032.
In 2027, PACB is forecast to generate $72,699,115,957 in revenue, with the lowest revenue forecast at $71,150,078,814 and the highest revenue forecast at $74,228,047,428.